Wellcome Sanger Institute
Sanger Institute Science Collaboration

Identification of novel drug targets in colorectal cancer.

We are using siKinome and genome-wide CRISPR/Cas9 lethality screens in colorectal cancer cell lines to identify novel vulnerabilities.